심부전용 소프트웨어 시장 : 유형별, 질환 유형별, 플랫폼별, 용도별, 최종 사용자별, 도입 모델별 시장 예측(2026-2032년)

The Heart Failure Software Market is projected to grow by USD 8.59 billion at a CAGR of 7.42% by 2032.

Heart failure software has moved from a supporting clinical tool to a core digital infrastructure layer for cardiology, population health, and value-based care. The category spans remote patient monitoring, clinical decision support, echocardiography and imaging analytics, care coordination, patient engagement, medication optimization, and interoperable data platforms used across hospitals, ambulatory practices, home health, and payers.

Demand is grounded in the clinical burden of heart failure: prevalence rises sharply with age, and leading cardiology societies estimate that heart failure affects about 1% to 2% of adults in developed markets and more than 10% of people over age 70. This makes scalable heart failure management software critical for reducing avoidable admissions, improving guideline-directed medical therapy, and supporting continuous monitoring beyond the hospital setting.

Transformative Shifts in the Heart Failure Software Landscape

The heart failure software landscape is being reshaped by the convergence of connected devices, cloud-based analytics, electronic health record integration, and reimbursement models that reward earlier intervention. Hospitals and cardiology groups are moving from episodic post-discharge follow-up to longitudinal digital pathways that combine symptoms, weight, blood pressure, heart rate, medication adherence, laboratory values, and device-generated signals.

A major shift is the operationalization of remote patient monitoring and virtual care. In the United States, Medicare reimbursement codes for remote physiologic monitoring and remote therapeutic monitoring have supported broader adoption, while Europe's digital health frameworks and national telehealth programs have encouraged structured deployment. At the same time, cybersecurity, clinical validation, interoperability, and clinician workflow fit have become decisive purchasing criteria.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating the shift from reactive heart failure management to predictive, personalized care. AI-enabled heart failure software can help identify deterioration patterns, prioritize high-risk patients, support imaging interpretation, and flag gaps in guideline-directed medical therapy. The strongest use cases are those embedded into clinician workflows, validated on representative populations, and monitored for performance drift.

The cumulative impact of AI is also changing competitive expectations. Buyers increasingly evaluate solutions on explainability, data governance, model validation, integration with EHR systems, and the ability to reduce alert fatigue. Regulatory oversight for software as a medical device, including FDA guidance and the European Union Medical Device Regulation, reinforces the need for transparent evidence, post-market monitoring, and responsible AI controls.

Key Regional Insights

North America remains a leading adoption region due to advanced cardiology infrastructure, EHR penetration, reimbursement support for remote monitoring, and a large diagnosed heart failure population. The United States anchors demand through health systems focused on readmission reduction, chronic care management, and value-based contracts, while Canada emphasizes integrated provincial care models, virtual health access, and remote care for rural and northern communities.

Europe benefits from mature public health systems, strong cardiology guidelines, and increasing digital health regulation under European frameworks. Germany, France, Italy, Spain, and the United Kingdom are prioritizing hospital-at-home models, telemonitoring pathways, virtual wards, and interoperable records. Asia-Pacific is expanding adoption as China, Japan, India, Australia, and South Korea address aging populations, cardiometabolic disease, and uneven specialist access through mobile health, connected devices, and AI-enabled clinical workflows.

Latin America, the Middle East, and Africa show rising need but more varied infrastructure maturity. Brazil and Mexico are advancing private-sector digital cardiology and public health modernization, while broader Latin American adoption depends on affordability, connectivity, and integration with fragmented care systems. GCC countries in the Middle East are investing in smart hospitals, national health information exchanges, and digital chronic disease programs. Across Africa, mobile-first care, workforce efficiency, earlier detection, and scalable follow-up tools are central to improving heart failure management where specialist access remains limited.

Key Group Insights

Within ASEAN, demand is shaped by high mobile connectivity, expanding private hospital networks, and the need to extend cardiology expertise beyond urban centers. Software vendors that support multilingual interfaces, mobile-first workflows, affordable remote monitoring models, and integration with primary care are better positioned across Indonesia, Thailand, Malaysia, Vietnam, Singapore, and the Philippines.

The GCC is advancing heart failure software through national digital health strategies, smart hospital investment, and growing attention to diabetes, obesity, hypertension, and cardiovascular risk. The European Union emphasizes privacy, interoperability, clinical evidence, and regulated digital health adoption, making compliance with GDPR, MDR, and emerging AI rules central to commercialization.

BRICS markets offer scale and diverse adoption pathways, from China's hospital digitization to India's mobile health ecosystem, Brazil's expanding private networks, Russia's cardiovascular disease management needs, and South Africa's demand for scalable specialist support. G7 countries represent high-value markets where evidence generation, reimbursement, cybersecurity, and integration with established EHR systems determine competitive success. NATO countries overlap substantially with advanced digital health markets, where resilience, data security, trusted infrastructure, and continuity of care are increasingly important procurement themes.

Key Country Insights

The United States is a major innovation and commercialization hub, supported by advanced EHR adoption, FDA pathways for digital health, Medicare remote monitoring reimbursement, and payer interest in reducing heart failure admissions. Canada offers opportunities through integrated provincial care, virtual care programs, and remote access initiatives. Mexico and Brazil are driven by growing cardiometabolic disease burdens, expanding private healthcare networks, and gradual modernization of digital health infrastructure.

In Europe, the United Kingdom emphasizes NHS digital transformation, virtual wards, and community-based heart failure management. Germany supports regulated digital health innovation and interoperability initiatives, France prioritizes telemonitoring reimbursement pathways, and Italy and Spain focus on regional care coordination and hospital-to-home models. Russia's market is shaped by domestic healthcare digitization and large cardiovascular disease needs.

China is scaling hospital digitization, connected care, and AI-enabled clinical platforms to support large patient volumes. India is advancing mobile-first chronic disease management through its digital public infrastructure and expanding telehealth use. Japan is focused on aging-related care efficiency and integrated monitoring for older adults, while Australia supports remote access for dispersed populations and chronic disease management across metropolitan and rural settings. South Korea combines advanced broadband infrastructure, strong digital hospital adoption, and policy support for connected healthcare innovation.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated heart failure software that demonstrates measurable impact on admissions, medication optimization, care team efficiency, and patient engagement. Procurement decisions are increasingly evidence-led, so vendors should invest in real-world studies, peer-reviewed outcomes, and health-economic models tailored to payer and provider priorities.

Software strategy should emphasize interoperability with EHRs, connected devices, pharmacy systems, imaging platforms, claims data, and patient portals. Vendors should design for clinician workflow, minimize alert fatigue, support equity across age and literacy groups, and implement rigorous cybersecurity and privacy controls. Partnerships with health systems, device manufacturers, payers, home health providers, and cardiology networks can accelerate adoption and strengthen data depth.

Research Methodology

This executive summary is built on secondary research from recognized clinical, regulatory, and public health sources, including cardiology society guidelines, government digital health programs, regulatory frameworks for software as a medical device, reimbursement policies, and epidemiological evidence on heart failure prevalence and aging populations.

The analysis synthesizes verified market signals across regions, groups, and countries by evaluating adoption drivers, clinical needs, infrastructure maturity, reimbursement environments, regulatory requirements, data protection rules, and technology readiness. Insights were screened for relevance to heart failure software, including remote monitoring, AI-enabled decision support, imaging analytics, care coordination, patient engagement, medication optimization, and interoperable clinical platforms.

Conclusion

Heart failure software is becoming essential to modern cardiovascular care as health systems face rising prevalence, aging populations, workforce constraints, and pressure to improve outcomes at lower cost. The strongest opportunities lie in platforms that connect clinical evidence, interoperable workflows, predictive analytics, and patient-centered engagement.

Artificial intelligence, remote monitoring, and value-based care will continue to define the direction of heart failure software, but trust will be the decisive differentiator. Vendors that prove clinical value, protect data, integrate seamlessly, and support equitable access are positioned to lead the next phase of digital heart failure management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Heart Failure Software Market, by Type

• 7.1. Knowledge Based
• 7.2. Non-Knowledge Based

8. Heart Failure Software Market, by Disease Type

• 8.1. Congenital Heart Failure
• 8.2. Left-Sided Heart Failure
• 8.3. Right-Sided Heart Failure

9. Heart Failure Software Market, by Platform

• 9.1. Integrated
• 9.2. Standalone

10. Heart Failure Software Market, by Application

• 10.1. Clinical Decision Support
• 10.2. Data Analytics
• 10.3. Electronic Medical Record Integration
• 10.4. Mobile & Patient-centric Applications
• 10.5. Predictive Analytics & Risk Stratification Tools
• 10.6. Remote Monitoring & Telehealth Platform

11. Heart Failure Software Market, by End-User

• 11.1. Clinics
• 11.2. Homecare Settings
• 11.3. Hospitals

12. Heart Failure Software Market, by Deployment Model

• 12.1. Cloud-Based Systems
• 12.2. On-Premises
• 12.3. Web-Based

13. Heart Failure Software Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Heart Failure Software Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Heart Failure Software Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AliveCor, Inc.
• 17.3. Astellas Pharma Inc.
• 17.4. Axis Clinical Software, Inc.
• 17.5. Biofourmis Inc.
• 17.6. Biome.io
• 17.7. BIOPAC Systems Inc.
• 17.8. Boston Scientific Corporation
• 17.9. Canon Medical Systems Corporation
• 17.10. Cardiac RMS, LLC by DocGo, Inc.
• 17.11. CitiusTech Inc.
• 17.12. Cleerly, Inc.
• 17.13. CV Medical Software
• 17.14. Dyad Medical Inc.
• 17.15. Eko Health Inc.
• 17.16. Elucid Bioimaging Inc.
• 17.17. Endotronix, Inc
• 17.18. Epic Systems Corporation
• 17.19. Foundry Innovation & Research 1 Ltd.
• 17.20. GE HealthCare Technologies Inc.
• 17.21. Heart Input Output Inc.
• 17.22. Implicity
• 17.23. International Business Machines Corporation
• 17.24. iRhythm Technologies, Inc.
• 17.25. Koninklijke Philips N.V.
• 17.26. Medtronic PLC
• 17.27. N. Harris Computer Corporation
• 17.28. NorthEast Monitoring, Inc.
• 17.29. Oracle Corporation
• 17.30. PaceMate, LLC
• 17.31. Pacertool AS
• 17.32. Precordior Ltd.
• 17.33. Siemens AG
• 17.34. Ultromics Limited
• 17.35. VectraCor Inc.
• 17.36. VUNO Inc.
• 17.37. ZOLL Medical Corporation